High-mobility group box-1 peptide ameliorates bronchopulmonary dysplasia by suppressing inflammation and fibrosis in a mouse model

Biochem Biophys Res Commun. 2023 Sep 3:671:357-365. doi: 10.1016/j.bbrc.2023.06.032. Epub 2023 Jun 9.


Background: This study aimed to examine the effect of the HMGB1 peptide on Bronchopulmonary dysplasia (BPD)-related lung injury in a mouse model.

Results: HMGB1 peptide ameliorates lung injury by suppressing the release of inflammatory cytokines and decreasing soluble collagen levels in the lungs. Single-cell RNA sequencing showed that the peptide suppressed the hyperoxia-induced inflammatory signature in macrophages and the fibrotic signature in fibroblasts. These changes in the transcriptome were confirmed using protein assays.

Conclusion: Systemic administration of HMGB1 peptide exerts anti-inflammatory and anti-fibrotic effects in a mouse model of BPD. This study provides a foundation for the development of new and effective therapies for BPD.

Keywords: Bronchopulmonary dysplasia; Chronic lung disorder; HMGB1; Mesenchymal stem cell; Peptide; Single-cell RNA sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Bronchopulmonary Dysplasia* / drug therapy
  • Bronchopulmonary Dysplasia* / genetics
  • Cytokines / adverse effects
  • Disease Models, Animal
  • Fibrosis
  • HMGB1 Protein* / metabolism
  • Humans
  • Hyperoxia* / pathology
  • Infant, Newborn
  • Inflammation / drug therapy
  • Inflammation / pathology
  • Lung / pathology
  • Lung Injury* / pathology
  • Mice


  • HMGB1 Protein
  • Cytokines